VIDEO: Tailor chronic pain interventions to patient’s clinical profile

ORLANDO – Address chronic pain with multiple modalities individualized by patient clinical profile, said Dr. Charles E. Argoff, professor of neurology and director of the Comprehensive Pain Center at Albany (N.Y.) Medical Center, in a video interview.

The neuroplastic changes that take place in the nervous system following a lesion or injury may respond in an aberrant manner in some patients, triggering chronic pain, and the clinician’s job is to find the right mix of interventions – pharmacologic, behavioral, and/or surgical – that best matches the patient’s clinical profile, he said at the meeting held by the American Pain Society and Global Academy for Medical Education. Global Academy and this news organization are owned by the same company.

Dr. Argoff reported financial relationships with Allergan, AstraZeneca, Depomed, Eli Lilly, Endo Pharmaceuticals, Forest Laboratories, Millennium Laboratories, Nektar Therapeutics, Pfizer, Xenoport, and Zogenix.

ORLANDO – Address chronic pain with multiple modalities individualized by patient clinical profile, said Dr. Charles E. Argoff, professor of neurology and director of the Comprehensive Pain Center at Albany (N.Y.) Medical Center, in a video interview.

The neuroplastic changes that take place in the nervous system following a lesion or injury may respond in an aberrant manner in some patients, triggering chronic pain, and the clinician’s job is to find the right mix of interventions – pharmacologic, behavioral, and/or surgical – that best matches the patient’s clinical profile, he said at the meeting held by the American Pain Society and Global Academy for Medical Education. Global Academy and this news organization are owned by the same company.

Dr. Argoff reported financial relationships with Allergan, AstraZeneca, Depomed, Eli Lilly, Endo Pharmaceuticals, Forest Laboratories, Millennium Laboratories, Nektar Therapeutics, Pfizer, Xenoport, and Zogenix.

ORLANDO – Address chronic pain with multiple modalities individualized by patient clinical profile, said Dr. Charles E. Argoff, professor of neurology and director of the Comprehensive Pain Center at Albany (N.Y.) Medical Center, in a video interview.

The neuroplastic changes that take place in the nervous system following a lesion or injury may respond in an aberrant manner in some patients, triggering chronic pain, and the clinician’s job is to find the right mix of interventions – pharmacologic, behavioral, and/or surgical – that best matches the patient’s clinical profile, he said at the meeting held by the American Pain Society and Global Academy for Medical Education. Global Academy and this news organization are owned by the same company.

Dr. Argoff reported financial relationships with Allergan, AstraZeneca, Depomed, Eli Lilly, Endo Pharmaceuticals, Forest Laboratories, Millennium Laboratories, Nektar Therapeutics, Pfizer, Xenoport, and Zogenix.